Researchers analyzed data from a 28-day clinical study of 146 patients, half of which took inhaled budesonide — sold as AstraZeneca’s Pulmicort — twice a day.
The drug cut the risk of urgent care or hospitalization by 90 percent within the study period and was also tied to a “quicker resolution of fever, symptoms, and fewer persistent symptoms.”
The study findings were published Feb. 4 on the medRxiv preprint server. The study has yet to be peer reviewed.
More articles on patient safety and outcomes:
Roche arthritis drug reduces COVID-19 death risk, Oxford research suggests
FDA updates guidance on ventilator splitting
Joint Commission issues alert on providing equitable care during pandemic
